Holen Sie sich die Stockscreener-App
26.57
5.44%
-1.53
Handel nachbörslich:
27.08
0.51
+1.92%
Schlusskurs vom Vortag:
$28.10
Offen:
$26.93
24-Stunden-Volumen:
1.84M
Relative Volume:
1.31
Marktkapitalisierung:
$3.31B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-9.1938
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
-15.92%
1M Leistung:
-6.97%
6M Leistung:
-43.83%
1J Leistung:
+12.16%
1-Tages-Spanne:
$26.23
$27.82
1-Wochen-Bereich:
$26.23
$30.64
52-Wochen-Spanne:
$22.24
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
26.57 | 3.31B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Yahoo Finance
When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com
Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - MarketScreener
Exclusive Look: Avidity Biosciences Reveals Latest Strategy at Needham Healthcare Conference - Stock Titan
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Australia
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - Morningstar
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com India
EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise
Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia
Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com
Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com
Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView
Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo Finance
New Duchenne Results Put Avidity On Course For Filing - insights.citeline.com
Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia
Citi maintains $70 target on Avidity Biosciences stock post-trial By Investing.com - Investing.com Canada
Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Benzinga India
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
Avidity Biosciences reports progress in DMD treatment trial - Investing.com India
Avidity Biosciences Announces Positive EXPLORE44 Trial Results - TipRanks
Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial -March 17, 2025 at 07:12 am EDT - Marketscreener.com
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skip - Financial Times
Bank of New York Mellon Corp Buys 59,295 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
BMO Capital Markets Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Citigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation - Nasdaq
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - The Malaysian Reserve
Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth By Investing.com - Investing.com South Africa
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation - MSN
Avidity Biosciences chief scientific officer sells $602,614 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Announces Upcoming Presentations at the Musc - GuruFocus.com
Avidity Biosciences chief scientific officer sells $602,614 in stock - Investing.com India
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avidity Biosciences Inc-Aktie (RNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
Apr 01 '25 |
Sale |
27.83 |
5,875 |
163,486 |
50,554 |
| Hughes Steven George | Chief Medical Officer |
Mar 20 '25 |
Sale |
31.06 |
9,578 |
297,491 |
72,850 |
| Boyce Sarah | President and CEO |
Mar 20 '25 |
Sale |
31.06 |
31,540 |
979,563 |
305,871 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 20 '25 |
Sale |
31.06 |
11,780 |
365,868 |
80,195 |
| MacLean Michael F | Chief Financial Officer |
Mar 20 '25 |
Sale |
31.06 |
7,935 |
246,425 |
96,720 |
| McCarthy Teresa | Chief Human Resources Officer |
Mar 20 '25 |
Sale |
31.06 |
7,778 |
241,583 |
97,130 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Option Exercise |
14.22 |
20,000 |
284,400 |
111,975 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Sale |
30.13 |
20,000 |
602,614 |
91,975 |
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):